Table 2. Dose and Incidence of Additional Propofol and Administered Cardiovascular Drugs.
| Group P1.5 (n = 47) | Group P2 (n = 47) | Group P2.5 (n = 47) | P value | P vs. Group P1.5 | ||
|---|---|---|---|---|---|---|
| Group P2 | Group P2.5 (P vs. Group P2) | |||||
| Complications | 26 (55.3%) | 8 (17.0%) | 19 (40.4%) | 0.001 | < 0.001* | 0.148 (0.012*) |
| Propofol | ||||||
| (mg) | 20 (0–50) | 0 (0–0) | 0 (0–50) | < 0.001 | < 0.001* | < 0.001* (0.042) |
| n (%) | 24 (51.1%) | 0 (0%) | 4 (8.5%) | < 0.001 | < 0.001* | < 0.001* (0.117) |
| Ephedrine | ||||||
| (mg) | 0 (0–5) | 0 (0–10) | 0 (0–20) | 0.018 | 0.340 | 0.007* (0.073) |
| n (%) | 5 (10.6%) | 8 (17.0%) | 15 (31.9%) | 0.030 | 0.370 | 0.012* (0.093) |
| Nicardipine | ||||||
| (mg) | 0 (0–0.5) | 0 (0–0) | 0 (0–0) | 0.131 | NA | NA |
| n (%) | 2 (4.3%) | 0 (0%) | 0 (0%) | 0.082 | NA | NA |
| Atropine | ||||||
| (mg) | 0 (0–0) | 0 (0–0) | 0 (0–0.5) | 0.365 | NA | NA |
| n (%) | 0 (0%) | 0 (0%) | 1 (2.1%) | 0.221 | NA | NA |
| Esmolol | ||||||
| (mg) | 0 (0–0) | 0 (0–0) | 0 (0–0) | > 0.999 | NA | NA |
| n (%) | 0 (0%) | 0 (0%) | 0 (0%) | > 0.999 | NA | NA |
Data are shown as the number of patients (%) or median (range). Complications: total incidence of additional propofol and administered cardiovascular drugs, NA: Statistical analysis is not applicable. *P < 0.017 was considered statistically significant (i.e., 0.05/3 = 0.017, Bonferroni correction).